Welcome to our dedicated page for Stereotaxis news (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis stock.
Stereotaxis, Inc. (STXS) is a global leader in innovative robotic technologies aimed at improving the treatment of arrhythmias and endovascular procedures. The company's mission focuses on the discovery, development, and delivery of advanced robotic systems, instruments, and information solutions tailored for the interventional laboratory. By leveraging cutting-edge innovations, Stereotaxis helps physicians provide superior patient care with robotic precision and safety, streamline lab efficiency, and enhance procedural information integration.
Stereotaxis boasts over 100 issued patents that form the backbone of its platform. The core components of its systems have received regulatory clearance in various regions including the United States, European Union, Japan, Canada, and China, among others. This broad regulatory approval underscores the global trust and reliance on Stereotaxis' technology.
The company's revenue streams are diversified across systems, disposables, royalties, and subleases, with a significant portion generated from disposables, services, and accessories. Notably, the majority of its revenue is derived from the United States.
Through continuous innovation and dedication to serving the medical community, Stereotaxis remains at the forefront of robotic medical technology, making significant strides in improving procedural outcomes and operational efficiencies in healthcare settings worldwide.
For the latest updates and more information, visit Stereotaxis.
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has appointed Nachum "Homi" Shamir to its Board of Directors. Shamir brings significant experience in growing global commercial organizations, scaling high-technology medical device operations, and executing successful mergers and acquisitions. He previously served as CEO of Luminex and Given Imaging, both of which were sold for over $1 billion each. Shamir currently chairs Mediwound and SSI Diagnostica.
This strategic appointment comes as Stereotaxis approaches significant inflection points. The company aims to benefit from Shamir's expertise in growing global commercial and operational capabilities, and refining its strategy to transform endovascular surgery through robotics. Stereotaxis' technology has been used to treat over 100,000 patients globally.
Penn Presbyterian Medical Center (PPMC) announces the successful implementation of the Genesis Robotic Magnetic Navigation System for treating heart rhythm patients, becoming the first hospital in the Northeast U.S. to adopt this advanced technology.
Developed by Stereotaxis (NYSE: STXS), the Genesis System enhances the precision and safety of cardiac ablation procedures used to treat arrhythmias—abnormal heart rhythms that affect millions globally and can lead to severe conditions like stroke and heart failure if untreated.
Dr. Benjamin D’Souza, Cardiac Electrophysiologist at PPMC, emphasized the system's role in improving patient outcomes by allowing tailored treatments. Stereotaxis CEO David Fischel expressed enthusiasm about the partnership, anticipating significant advancements in patient care and clinical research.
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular interventions, has received CE Mark recertification under the EU's new Medical Device Regulation (MDR). This recertification covers all Stereotaxis devices available in Europe and adheres to the stringent standards and requirements of MDR, which aims to enhance clinical safety and market access for medical devices. The updated EU Quality Management System Certificate confirms compliance with MDR, supporting future regulatory clearances for upcoming innovations. This achievement reflects Stereotaxis' commitment to high-quality devices and patient care, culminating from years of diligent work by the team.
Stereotaxis (NYSE: STXS) has announced that Hospital Santa Maria della Pietà in Nola, Southern Italy, has launched the region's first robotic cardiac heart program. The hospital has successfully treated patients with heart rhythm disorders using the Genesis Robotic Magnetic Navigation (RMN) system, making it the first in Italy to adopt this technology. Dr. Mario Volpicelli, Head of the Electrophysiology Unit, emphasized the precision and control offered by the Genesis RMN system in targeting arrhythmias, thereby minimizing patient risk. Tens of millions suffer from arrhythmias globally, which can increase risks of stroke, heart failure, and sudden cardiac arrest if untreated. General Manager Giuseppe Russo and Chief of Cardiology Luigi Caliendo praised the system for revolutionizing cardiac treatment in Italy. Stereotaxis Chairman and CEO David Fischel highlighted the partnership's commitment to advancing patient care and innovation in electrophysiology.
Stereotaxis (NYSE: STXS), a leader in surgical robotics, announced its invitation to present at the HRS Africa Summit 2024. The presentation will showcase their innovative robotic solution to provide high-quality cardiac ablation therapy in underserved African regions. The technology utilizes telerobotic presence, enabling remote operations by physicians. Stereotaxis' system, installable on a semi-trailer truck, offers scalable and cost-effective solutions, connecting expert electrophysiologists with local patients through satellite internet. This initiative aims to address the lack of electrophysiology (EP) labs in Africa, where 80% of countries lack such facilities. The presentation is scheduled for May 16th, during the Heart Rhythm Society Scientific Sessions in Boston.
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, reported financial results for Q1 2024, ending March 31. Revenue grew 5% YoY to $6.9M, with system revenue at $2.6M and recurring revenue at $4.3M. Gross margin was 58%. Operating expenses were $8.7M, including $2.6M in non-cash stock compensation. Adjusted operating expenses were $6.1M, down from $6.9M YoY. Operating loss and net loss were ($4.7M) and ($4.5M), respectively, improving from ($5.6M) and ($5.3M) YoY. Excluding non-cash expenses, adjusted operating and net loss were ($2.2M) and ($1.9M). Cash and equivalents stood at $18.2M with no debt. The company reported progress in regulatory submissions and technological advancements, including the MAGiC catheter and a new robot.
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announced a definitive agreement to acquire Access Point Technologies EP (APT). APT, based in Minnesota, develops electrophysiology catheters used in cardiac ablation procedures. This acquisition enhances Stereotaxis' catheter development, manufacturing capabilities, and provides commercial synergies. The deal includes upfront and contingent payments in Stereotaxis common stock, with APT expected to contribute approximately $5 million in annual revenue post-acquisition. The transaction is subject to customary closing conditions and is anticipated to close in Q3 2024. The acquisition aligns with Stereotaxis' strategy to innovate in endovascular surgery and improve arrhythmia treatments.
FAQ
What is the current stock price of Stereotaxis (STXS)?
What is the market cap of Stereotaxis (STXS)?
What does Stereotaxis, Inc. specialize in?
What is the mission of Stereotaxis, Inc.?
Where has Stereotaxis' technology received regulatory clearance?
What are the main revenue streams for Stereotaxis, Inc.?
Who are the key executives at Stereotaxis, Inc.?
How does Stereotaxis' technology benefit physicians?
How many patents does Stereotaxis hold?
What geographic region generates the majority of Stereotaxis' revenue?
What types of procedures are enhanced by Stereotaxis' technology?
Where can I find more information about Stereotaxis, Inc.?
